Jaimina Gharia, Shriya Pimplaskar, Department of Life Sciences, School of Science, GSFC University, Vadodara 391750, Gujarat, India
Akhilesh Prajapati, Department of Life Sciences, Division of Biotechnology, School of Science, GSFC University, Vadodara 391750, Gujarat, India
Co-first authors: Jaimina Gharia and Shriya Pimplaskar.
Author contributions: Gharia J, Pimplaskar S, and Prajapati A jointly contributed to the design, discussion, and writing of the review manuscript; AP conceptualized the idea for the review, prepared the study summaries, supervised the overall work, and critically revised the manuscript.
Supported by GSBTM, DST Government of Gujarat for Financial Support to the Prostate Cancer Research Project at GSFC University, Vadodara, No. GSBTM/RSS/E-FILE/30/2024/0021/04306791.
Conflict-of-interest statement: All authors declare that they have no competing interests.
Corresponding author: Akhilesh Prajapati, PhD, Senior Assistant Professor, Department of Life Sciences, Division of Biotechnology, School of Science, GSFC University, Vadodara 391750, Gujarat, India. akhileshbiotech06@gmail.com
Received: March 13, 2025 Revised: April 22, 2025 Accepted: June 3, 2025 Published online: July 24, 2025 Processing time: 131 Days and 20.7 Hours
Core Tip
Core Tip: Three-dimensional (3D) bioprinting is revolutionizing prostate cancer (PCa) research by replicating tumor microenvironments, enabling drug screening, and advancing personalized medicine. By mimicking the extracellular matrix and incorporating stromal and immune components, bioprinted models enhance physiological relevance. This technology facilitates targeted therapies by screening novel drugs tailored to individual patient profiles. However, challenges such as scalability, bioink optimization, and regulatory frameworks remain. Advances in microfluidic-assisted printing and artificial intelligence driven optimization can improve reproducibility. Integrating bioprinted models with organ-on-a-chip systems further enhances translational research. Collaborative efforts will accelerate clinical applications, positioning 3D bioprinting as a game-changer in personalized PCa treatment.
